FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality
You may also be interested in...
EU Proposed Regulation Raises Concerns From China’s API Exporters
EU draft guidance calls for greater clarity on the source of API, putting many Chinese manufacturers in a tough position.
SFDA Revises China GMP Guidelines; Seeks Industry Comments On Impact To Local Industry
SHANGHAI - China's State FDA revised its Good Manufacturing Practices Guidelines, and is asking for industry feedback on how the guidelines would affect local pharmaceutical companies, SFDA Deputy Director Wu Zhen said during a forum on drug safety and healthcare reform in Beijing April 28
U.S. FDA Launches First Overseas Office in Beijing
U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress